Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1026572 | 0.84 | ALDH1A1 (0.48) | KDM4EALDH1A1L3MBTL1LMNAGAA | |
| SCHEMBL11776219 | 0.84 | GRM5 (0.33) | — | |
| SCHEMBL454402 | 0.83 | ALDH1A1 (0.43) | KDM4EALDH1A1L3MBTL1LMNAGAA | |
| SCHEMBL169677 | 0.78 | GRM5 (0.40) | KDM4EALDH1A1L3MBTL1LMNAGAA | |
| SCHEMBL16116339 | 0.75 | KDM4E (0.36) | KDM4EALDH1A1L3MBTL1LMNAGAA | |
| SCHEMBL16379694 | 0.74 | CHEK1 (0.37) | KDM4EALDH1A1L3MBTL1LMNAGAA | |
| SCHEMBL455706 | 0.73 | — | — | |
| SCHEMBL9024185 | 0.72 | CYP11B2 (0.53) | EGLN2CHEK1GABRA1GABRG2GABRB3 | |
| SCHEMBL14061390 | 0.72 | GRM5 (0.43) | CHEK1 | |
| SCHEMBL15903117 | 0.72 | GRM5 (0.36) | KDM4EALDH1A1L3MBTL1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234390-A1 | NOVEL COMPOUND AND THEIR USE | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-09-16 | — | — | US | claimed |
| EP-2170874-A2 | NOVEL COMPOUNDS AND THEIR USE | Orchid Research Laboratories Limited (IN) | 2010-04-07 | — | — | EP | claimed |
| WO-2009001192-A2 | NOVEL COMPOUNDS AND THEIR USE | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2008-12-31 | — | — | WO | claimed |
| WO-2023212510-A1 | METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | PRAETEGO INC (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230338344-A1 | AMPK Activators and Methods of Use Thereof | BIOVERATIV THERAPEUTICS INC. (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4221700-A1 | AMPK ACTIVATORS AND METHODS OF USE THEREOF | Bioverativ Therapeutics Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-4007632-A1 | INHIBITORS OF ADVANCED GLYCATION END PRODUCTS | Praetego, Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| CN-114502546-A | Inhibitors of advanced glycation endproducts | 普拉特戈公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20210163450-A1 | Inhibitors of Advanced Glycation End Products | PRAETEGO INC | 2021-06-03 | — | — | US | disclosed |
| WO-2021022215-A1 | INHIBITORS OF ADVANCED GLYCATION END PRODUCTS | KHALIFAH RAJA G (US) | 2021-02-04 | — | — | WO | disclosed |
| US-9783527-B2 | Indazole ureas and method of use | ABBVIE INC. (US) | 2017-10-10 | — | — | US | disclosed |
| EP-1740579-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | Abbott Laboratories (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006083673-A2 | PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF C-JUN N-TERMINAL KINASES | ABBOTT LABORATORIES (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | ABBVIE INC. | 2006-08-03 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005095387-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050171132-A1 | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists | XIN ZHILI (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | KOSOGOF CHRISTI (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005030734-A1 | DIAMINOPYRIMIDINE DERIVATIVES AS SELECTIVE GROWTH HORMONE SECRECTGOGUE RECEPTOR (GHS-R) ANTAGONISTS | ABBOTT LABORATORIES (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | MAPKAPK3, MAP3K3, MAPK3 | KDM4E 2987/4885ALDH1A1 4339/4885L3MBTL1 1511/4885 |
| US-20230338344-A1 | AMPK Activators and Methods of Use Thereof | PRKAG2, PRKAG3, PRKAG1 | KDM4E 2836/4885ALDH1A1 952/4885L3MBTL1 2204/4885 |
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | GHSR, GIPR, GPR119 | KDM4E 1308/4885ALDH1A1 2435/4885L3MBTL1 4050/4885 |
| US-20050171132-A1 | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists | GHSR, GIPR, GPR119 | KDM4E 1366/4885ALDH1A1 3084/4885L3MBTL1 4194/4885 |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | KDM4E 1449/4885ALDH1A1 3901/4885L3MBTL1 3013/4885 |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | GPR119, GIPR, GCGR | KDM4E 1540/4885ALDH1A1 2333/4885L3MBTL1 4387/4885 |
| US-20210163450-A1 | Inhibitors of Advanced Glycation End Products | AGER, GLA, GPR119 | KDM4E 1590/4885ALDH1A1 470/4885L3MBTL1 2463/4885 |
| US-20100234390-A1 | NOVEL COMPOUND AND THEIR USE | HTRA1, PRSS1, PRNP | KDM4E 4135/4885ALDH1A1 3866/4885L3MBTL1 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.